{
  "@context": [
    "file://domain/_contexts/base.jsonld",
    "file://domain/_contexts/medicine.jsonld"
  ],
  "@type": [
    "EducationalResource",
    "MedicalGuideline"
  ],
  "@id": "health-sciences:medicine:cardiology:cardio-009",
  "metadata": {
    "version": "4.0.0",
    "created": "2026-01-09T01:50:10.000Z",
    "contributors": [
      "copilot-agent",
      "quality-enhancement-agent",
      "cardiology-knowledge-base"
    ],
    "confidence": 0.96,
    "status": "validated",
    "modified": "2026-01-11T14:36:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/cardiology",
    "type": "treatment",
    "difficulty": "intermediate",
    "importance": "high",
    "aku_id": "009",
    "keywords": [
      "atrial fibrillation",
      "rate control",
      "beta-blocker",
      "calcium channel blocker",
      "digoxin"
    ],
    "medical_specialty": "cardiology",
    "clinical_context": "arrhythmia_management"
  },
  "content": {
    "title": "Atrial Fibrillation Rate Control",
    "summary": "Pharmacologic strategies for controlling ventricular rate in atrial fibrillation",
    "key_points": [
      "Rate control is first-line for most AF patients",
      "Lenient rate control (<110 bpm) is acceptable for most",
      "Beta-blockers and non-DHP CCBs are first-line agents",
      "Digoxin is second-line, useful in HFrEF",
      "AV node ablation + pacemaker for refractory cases",
      "Avoid rate-control agents in pre-excitation (WPW)"
    ],
    "statement": {
      "text": "Rate control in atrial fibrillation aims to reduce ventricular rate to improve symptoms without attempting to restore sinus rhythm. First-line agents include beta-blockers and non-dihydropyridine calcium channel blockers. Lenient rate control (resting HR <110 bpm) is non-inferior to strict control (<80 bpm) for most patients.",
      "formal": "AF Rate Control = Beta-blocker OR Non-DHP CCB \u2192 Add digoxin if needed \u2192 Lenient target (<110) acceptable"
    },
    "explanation": {
      "intuition": "In AF, the atria fire chaotically at 350-600/min, but the AV node filters these impulses. Rate control drugs slow AV conduction, reducing how many impulses reach the ventricles. A slower, more regular ventricular rate improves cardiac output and symptoms.",
      "key_insight": "The RACE II trial showed lenient rate control (<110 bpm at rest) is as safe as strict control (<80 bpm), with easier drug titration and fewer visits. Reserve strict control for persistent symptoms despite lenient control."
    },
    "definitions_glossary": {
      "rate_control": "Strategy to slow ventricular rate in AF without restoring sinus rhythm",
      "lenient_rate_control": "Target resting HR <110 bpm",
      "strict_rate_control": "Target resting HR <80 bpm and exercise HR <110 bpm",
      "beta_blocker": "Drugs blocking beta-adrenergic receptors, slowing AV conduction",
      "non_DHP_CCB": "Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) - slow AV node",
      "DHP_CCB": "Dihydropyridine CCBs (amlodipine) - DON'T control rate (peripheral vasodilators)",
      "digoxin": "Cardiac glycoside enhancing vagal tone to slow AV conduction",
      "AV_node_ablation": "Catheter ablation of AV node + permanent pacemaker for refractory rate control",
      "chronotropic_incompetence": "Inability to appropriately increase HR with activity",
      "tachycardia_induced_cardiomyopathy": "HF from prolonged uncontrolled tachycardia; reversible with rate control",
      "rapid_ventricular_response": "RVR - ventricular rate >100 bpm in AF",
      "congestive_symptoms": "Dyspnea, edema from inadequate cardiac output in uncontrolled AF"
    }
  },
  "clinical_features": {
    "pathophysiology": {
      "AV_node_conduction": "AV node has intrinsic conduction slowing properties; rate-control agents enhance this",
      "drug_mechanisms": {
        "beta_blockers": "Block sympathetic stimulation of AV node \u2192 prolonged AV refractoriness",
        "non_DHP_CCBs": "Block L-type calcium channels in AV node \u2192 slower conduction",
        "digoxin": "Enhances vagal tone (parasympathetic) \u2192 decreased AV conduction; less effective with activity"
      }
    },
    "treatment_options": {
      "first_line_agents": {
        "beta_blockers": {
          "drugs": [
            "Metoprolol",
            "Atenolol",
            "Carvedilol (if HFrEF)",
            "Bisoprolol"
          ],
          "dosing": "Metoprolol tartrate 25-100mg BID, succinate 50-200mg daily",
          "advantages": "Good exercise rate control, beneficial in CAD and HFrEF",
          "cautions": "Avoid in decompensated HF, severe asthma, bradycardia"
        },
        "non_DHP_CCBs": {
          "drugs": [
            "Diltiazem",
            "Verapamil"
          ],
          "dosing": "Diltiazem 120-360mg daily (extended-release), Verapamil 120-360mg daily",
          "advantages": "Good rate control, no beta-blocker side effects",
          "contraindications": "HFrEF (negative inotropic effect), hypotension"
        }
      },
      "second_line_agents": {
        "digoxin": {
          "dosing": "0.125-0.25mg daily (reduce in elderly, renal impairment)",
          "advantages": "Useful in HFrEF, neutral effect on BP",
          "limitations": "Less effective during exercise (sympathetic activation overrides vagal effect)",
          "monitoring": "Serum digoxin level 0.5-1.0 ng/mL; watch for toxicity"
        },
        "amiodarone": {
          "role": "Last resort for rate control when others fail or contraindicated",
          "caution": "Significant toxicity; prefer other options"
        }
      },
      "acute_rate_control": {
        "stable_patient": "IV metoprolol 5mg q5min x3 or IV diltiazem 0.25mg/kg bolus \u2192 drip",
        "unstable_with_RVR": "Synchronized cardioversion if hemodynamically unstable"
      },
      "refractory_cases": {
        "AV_node_ablation": {
          "indication": "Persistent symptoms despite maximal medical rate control",
          "procedure": "Catheter ablation of AV node \u2192 pacemaker dependent",
          "outcome": "Excellent rate control; pacemaker required for life"
        }
      }
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Atrial Fibrillation Rate Control"
    },
    "altLabel": [
      {
        "@language": "en",
        "@value": "AF Rate Control"
      },
      {
        "@language": "en",
        "@value": "Ventricular Rate Control in AF"
      }
    ],
    "definition": {
      "@language": "en",
      "@value": "Pharmacologic and procedural strategies to control ventricular rate in atrial fibrillation without restoring sinus rhythm"
    },
    "notation": "cardio-009"
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "49436004",
      "description": "Atrial fibrillation",
      "matchType": "broadMatch"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "MeSH",
      "codeValue": "D001281",
      "description": "Atrial Fibrillation",
      "matchType": "broadMatch"
    }
  ],
  "pedagogical": {
    "target_audience": [
      "medical_students",
      "internal_medicine_residents",
      "hospitalists"
    ],
    "estimated_time": "30min",
    "difficulty_curve": 0.65,
    "learning_objectives": [
      "Select appropriate first-line rate control agent based on comorbidities",
      "Distinguish lenient vs strict rate control goals",
      "Recognize when to avoid non-DHP CCBs (HFrEF)",
      "Identify indications for AV node ablation"
    ],
    "clinical_pearls": [
      "Non-DHP CCBs contraindicated in HFrEF - use beta-blockers + digoxin",
      "Digoxin less effective during exercise - combine with beta-blocker if active patient",
      "Lenient control (<110) is usually sufficient - don't over-titrate",
      "Tachycardia-mediated cardiomyopathy is reversible with adequate rate control",
      "NEVER use AV nodal blockers in WPW with AF (can trigger VF)"
    ],
    "board_yield": {
      "usmle_step2": "High",
      "internal_medicine_boards": "Very High"
    }
  },
  "relationships": {
    "prerequisites": [
      {
        "id": "health-sciences:medicine:cardiology:cardio-007",
        "title": "Atrial Fibrillation Definition",
        "strength": 1.0
      }
    ],
    "skos:broader": [
      {
        "@id": "health-sciences:medicine:cardiology:cardio-007",
        "@type": "skos:Concept",
        "skos:prefLabel": "Atrial Fibrillation"
      }
    ],
    "skos:related": [
      {
        "@id": "health-sciences:medicine:cardiology:cardio-010",
        "@type": "skos:Concept",
        "skos:prefLabel": "AF Rhythm Control"
      }
    ],
    "owl:sameAs": [
      "http://www.wikidata.org/entity/Q207104"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-11T14:36:00.000Z",
    "sources": [
      {
        "source": "2023 ACC/AHA/ACCP/HRS AF Guideline",
        "type": "clinical_guideline",
        "year": 2023,
        "confidence": 1.0
      }
    ]
  },
  "quality_assessment": {
    "CQS": 0.93,
    "completeness": 0.94,
    "accuracy": 0.96,
    "clarity": 0.93,
    "pedagogical_quality": 0.92,
    "ontology_alignment": 0.93,
    "last_assessment": "2026-01-11T14:36:00.000Z",
    "assessor": "quality-enhancement-agent"
  },
  "owl:sameAs": "http://dbpedia.org/resource/Atrial_fibrillation",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q207104"
}